Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adriamycin + cyclophosphamide + paclitaxel + propranolol
- Development stage
- Unknown
- Lead developer
- Farmitalia
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a four-drug combination regimen consisting of adriamycin (doxorubicin), cyclophosphamide, paclitaxel, and propranolol. Adriamycin (doxorubicin) is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis in cancer cells. Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division. Paclitaxel is a taxane that stabilizes microtubules and prevents their depolymerization, thereby inhibiting mitosis. Propranolol is a non-selective beta-adrenergic receptor antagonist traditionally used for cardiovascular indications; it has shown anti-angiogenic properties and potential to reduce metastasis in preclinical cancer models. This combination has been studied primarily in the neoadjuvant treatment of breast cancer[1][2][5].
- Other names
- AC-T plus propranololdoxorubicin + cyclophosphamide + paclitaxel + propranolol
02
Targets
TOP2A (DNA topoisomerase II)ADRB1 (β1)TOP2B (DNA topoisomerase II beta)DNA
Beyond the preview
Go deeper on adriamycin + cyclophosphamide + paclitaxel + propranolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adriamycin + cyclophosphamide + paclitaxel + propranolol.